Showing 4,321 - 4,340 results of 20,793 for search '"therapy"', query time: 0.15s Refine Results
  1. 4321

    Using Topomer Comparative Molecular Field Analysis to Elucidate Activity Differences of Aminomethylenethiophene Derivatives as Lysyl Oxidase Inhibitors: Implications for Rational Design of Antimetastatic Agents for Cancer Therapy by Jing Han, Guochao Yan, Jianping Feng, Xianglin Yang, Yuan Zhou

    Published 2020-01-01
    “…The topomer CoMFA modeling could provide a quantitative perspective into the structure-activity relationship of AMT derivatives and potentially speed up the rational design of LOX inhibitors as antimetastatic agents for cancer therapy.…”
    Get full text
    Article
  2. 4322
  3. 4323
  4. 4324

    Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study by Jin Yin, Xiaoya Cai, Bingxin Qian, Ying Liu, Dengju Li

    Published 2024-12-01
    “…Conclusions Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost‐efficiency and resource management in health care.…”
    Get full text
    Article
  5. 4325
  6. 4326

    Montelukast as Add-On Therapy with Inhaled Corticosteroids or Inhaled Corticosteroids and Long-Acting Beta-2-Agonists in the Management of Patients Diagnosed with Asthma and Concurrent Allergic Rhinitis (The RADAR Trial) by Paul K Keith, Caroline Koch, Michel Djandji, Jacques Bouchard, Eliofotisti Psaradellis, John S Sampalis, R Robert Schellenberg, R Andrew McIvor

    Published 2009-01-01
    “…OBJECTIVE: To evaluate the effectiveness of montelukast as add-on therapy for patients diagnosed with asthma and concurrent allergic rhinitis who remain uncontrolled while receiving inhaled corticosteroid (ICS) monotherapy or ICS/long-acting beta-2-agonist (LABA) therapy in a community practice setting.…”
    Get full text
    Article
  7. 4327
  8. 4328
  9. 4329

    Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy by Jan Heilinger, Katrin Sabine Roth, Henning Weis, Antonis Fink, Jasmin Weindler, Felix Dietlein, Philipp Krapf, Klaus Schomäcker, Bernd Neumaier, Markus Dietlein, Alexander Drzezga, Carsten Kobe

    Published 2025-01-01
    “…This may impact treatment decisions and outcomes, as eligibility for PSMA-directed radioligand therapy is usually assessed by comparing tumoral uptake to normal liver uptake as a reference. …”
    Get full text
    Article
  10. 4330

    Two-year follow-up of gait and postural control following initiation of recombinant human tripeptidyl intracerebroventricular enzyme replacement therapy in two atypical CLN2 patients by Rahul Soangra, Marybeth Grant-Beuttler, Harriet Chang, Raymond Y. Wang

    Published 2025-01-01
    “…Ambulatory CLN2 patients typically receive standard of care treatment through biweekly intracerebroventricular (ICV) enzyme replacement therapy (ERT) involving recombinant human tripeptidyl peptidase 1, known as cerliponase alfa (Brineura®, Biomarin Pharmaceuticals). …”
    Get full text
    Article
  11. 4331
  12. 4332
  13. 4333
  14. 4334
  15. 4335
  16. 4336

    Study of cardiovascular risk in type 2 diabetic patients in the acute phase of the coronavirus infection and post-COVID period on the background of therapy with sodium-glucose cotransporter-2 inhibitors by N.M. Kushnarоva, O.V. Zinych, A.A. Shuprovych, K.P. Komisarenko

    Published 2024-12-01
    “…The purpose of the study was to assess the effect of antidiabetic therapy using sodium-glucose cotransporter-2 inhibitors (SGLT2i) on serum level of cardiovascular markers, ST2 peptide and homocysteine, in patients with T2DM in the post-COVID period compared to standard therapy (metformin/sulfonylurea derivatives). …”
    Get full text
    Article
  17. 4337
  18. 4338

    30-Day and 1-Year Mortality after Transcatheter Aortic Valve Replacement: The Impact of Balloon Aortic Valvuloplasty as a Bridging Therapy in a Portuguese Tertiary Center by Francisco B. Albuquerque, Bárbara L. Teixeira, André Grazina, Rúben Ramos, António Fiarresga, Alexandra Castelo, Tiago Mendonça, Inês Rodrigues, Duarte Cacela, Rui Ferreira

    Published 2024-01-01
    “…We aimed to compare 30-day and 1-year all-cause mortality between patients submitted to BAV as a bridging therapy before definite TAVR and patients submitted directly to TAVR. …”
    Get full text
    Article
  19. 4339

    Efficacy of non-invasive ventilation and oxygen therapy on immunocompromised patients with acute hypoxaemic respiratory failure: protocol for a systematic review and meta-analysis of randomised controlled trials by Juhong Shi, Gang Liu, Meng Wang, Tao Wang, Yi Li, Yi Yang, Xuezhong Yu, Huadong Zhu, Yong Ma, Zongru Li, Lixi Zhang, Kun He, Jianqiang He

    Published 2017-06-01
    “…The use of non-invasive ventilation (NIV) or oxygen therapy among these patients remains controversial, according to the inconsistent results of several randomised clinical trials (RCTs). …”
    Get full text
    Article
  20. 4340